BRPI0509459A - sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados - Google Patents

sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Info

Publication number
BRPI0509459A
BRPI0509459A BRPI0509459-3A BRPI0509459A BRPI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A BR PI0509459 A BRPI0509459 A BR PI0509459A
Authority
BR
Brazil
Prior art keywords
retinoid
manufacturing methods
related manufacturing
drug delivery
sustained release
Prior art date
Application number
BRPI0509459-3A
Other languages
English (en)
Inventor
Patrick M Hughes
Orest Olejnik
Glenn T Huang
Joan-En Chang-Lin
Thierry Nivaggioli
Michele Boix
Christian Sarrazin
Jane Guo Shiah
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0509459A publication Critical patent/BRPI0509459A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMAS DE DISTRIBUIçãO DE DROGA INTRA-OCULAR COM LIBERAçãO SUSTENTADA CONTENDO RETINóIDE E MéTODOS DE FABRICAçãO RELACIONADOS". A presente invenção refere-se a implantes intra-oculares bio-compatíveis incluem um componente retinóide e um polímero biodegradável que é eficaz para facilitar a liberação do componente retinóide nos olhos durante um período de tempo prolongado. Os agentes terapêuticos dos implantes podem estar associados a uma matriz polimérica biodegradável, tal como uma matriz que é substancialmente isenta de um álcool polivinílico. Os implantes podem ser colocados nos olhos para tratar ou reduzir a ocorrência de uma ou mais condições oculares, tal como lesão retinal, incluindo glaucoma e vítreo-retinopatia proliferativa.
BRPI0509459-3A 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados BRPI0509459A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56733904P 2004-04-30 2004-04-30
US62992804P 2004-11-22 2004-11-22
US11/119,024 US20050271705A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery system and related methods
PCT/US2005/015018 WO2005107707A1 (en) 2004-04-30 2005-04-29 Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Publications (1)

Publication Number Publication Date
BRPI0509459A true BRPI0509459A (pt) 2007-09-04

Family

ID=34972221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509459-3A BRPI0509459A (pt) 2004-04-30 2005-04-29 sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados

Country Status (9)

Country Link
US (3) US20050271705A1 (pt)
EP (1) EP1765284A1 (pt)
JP (1) JP2007535563A (pt)
AR (1) AR056254A1 (pt)
AU (1) AU2005240078A1 (pt)
BR (1) BRPI0509459A (pt)
CA (1) CA2565285A1 (pt)
TW (1) TW200538163A (pt)
WO (1) WO2005107707A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
JP5890182B2 (ja) * 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
WO2012021733A2 (en) 2010-08-12 2012-02-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
TW201311295A (zh) * 2011-06-03 2013-03-16 Allergan Inc 對皮脂腺之類視色素化合物之目標遞送
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
US9492431B2 (en) 2012-11-08 2016-11-15 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
CN105228614A (zh) 2012-11-28 2016-01-06 阿菲欧斯公司 用于治疗神经退化疾病和其它疾病的组合治疗剂和方法
US10123988B2 (en) 2013-03-15 2018-11-13 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
ES2694831T3 (es) 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
EP3099290A1 (en) 2014-01-28 2016-12-07 Allergan, Inc. Topical retinoid formulations and methods of use
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
WO2015187840A2 (en) * 2014-06-03 2015-12-10 Duke University Methods and formulations for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
JP7023868B2 (ja) 2016-06-08 2022-02-22 クレメンティア ファーマシューティカルズ，インコーポレイテッド 異所性骨化を治療するための方法
CA3043807A1 (en) 2016-11-16 2018-05-24 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
CN111358766A (zh) * 2020-04-13 2020-07-03 青岛大学 一种包载他扎罗汀的plga纳米粒及其制备方法、用途
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
JP2001513369A (ja) * 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
WO2002049620A2 (en) * 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
WO2003082081A2 (en) * 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing

Also Published As

Publication number Publication date
TW200538163A (en) 2005-12-01
US20090163550A1 (en) 2009-06-25
WO2005107707A1 (en) 2005-11-17
JP2007535563A (ja) 2007-12-06
US20110076318A1 (en) 2011-03-31
CA2565285A1 (en) 2005-11-17
EP1765284A1 (en) 2007-03-28
AR056254A1 (es) 2007-10-03
US20050271705A1 (en) 2005-12-08
AU2005240078A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0509459A (pt) sistemas de distribuição de droga intraocular com liberação sustentada contendo retinóide e métodos de fabricação relacionados
BRPI0510472A (pt) implantes intra-oculares de liberação prolongada antiexcitotóxicos e métodos relacionados
BRPI0510471A (pt) derivado de estradiol ou um derivado de estratopona contendo implante intra-ocular de liberação constante bem como métodos relacionados de fabricação
Lee et al. Biodegradable implants for sustained drug release in the eye
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
BRPI0509461A (pt) implantes intravìtreos compreendendo microesferas que encapsulam um inibidor de tirosina cinase e um polìmero biodegradável
MX2010012022A (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular.
BRPI1007318A2 (pt) distribuição com liberação sustentada de um ou mais agentes.
Barequet et al. Provision of anesthesia with single application of lidocaine 2% gel
BR112012026535A2 (pt) redução de pressão intraocular com implantes de bimatoprost intracameral
TW200605918A (en) Biodegradable intravitreal tyrosine kinase implants
BRPI0513243A (pt) composições oftálmicas e métodos para tratar condições oftálmicas
JP2010507686A5 (pt)
SG170816A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
BRPI0509333A (pt) implantes intraoculares esteróides tendo uma liberação gradual prolongada por um perìodo de mais de dois meses
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
BRPI0607606A2 (pt) formulações lìquidas para tratamento de doenças ou condições
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
RU2011106329A (ru) Глазное устройство, обладающее способностью доставки терапевтического средства и способ получения такового
WO2010093873A3 (en) Drug delivery through hydrogel plugs
BR112013018739A2 (pt) sistema de distribuição de medicamento ocular
SG10201809363SA (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
JP2014530904A (ja) 円錐角膜の治療に有効であり、イオントフォレシスにより導入される改良された架橋結合組成物
IL273715B2 (en) Subcutaneous biodegradable naltrexone implant and accompanying behavioral program for weight loss in a patient

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.